Heat Biologics, Inc., a clinical stage cancer immunotherapy company, has developed its next-generation combination immunotherapy platform, which combines a pan-antigen T cell priming vaccine and T cell co-stimulator in a single product. This platform, named ComPACT, has been engineered to incorporate various fusion proteins targeting co-stimulatory receptors—OX40, ICOS, 4-1BB—enabling the combination of two important immunotherapy pathways in a single therapy. “It is now widely recognized in ...